Anti-FGFR1 Oncogene Partner antibody (ab229012)
Key features and details
- Rabbit polyclonal to FGFR1 Oncogene Partner
- Suitable for: IHC-P, WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-FGFR1 Oncogene Partner antibody
See all FGFR1 Oncogene Partner primary antibodies -
Description
Rabbit polyclonal to FGFR1 Oncogene Partner -
Host species
Rabbit -
Tested applications
Suitable for: IHC-P, WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment within Human FGFR1OP-FGFR1 (internal sequence). The exact sequence is proprietary.
Database link: O95684 -
Positive control
- WB: Raji whole cell lysate. IHC-P: Human lung cancer tissue.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.00
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 1.21% Tris, 0.75% Glycine, 20% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab229012 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
1/100 - 1/1000.
|
|
WB |
1/500 - 1/3000. Predicted molecular weight: 43 kDa.
|
Notes |
---|
IHC-P
1/100 - 1/1000. |
WB
1/500 - 1/3000. Predicted molecular weight: 43 kDa. |
Target
-
Function
Required for anchoring microtubules to the centrosomes. -
Tissue specificity
Ubiquitous. Highly expressed in heart, liver, muscle, kidney, intestine, colon, adrenal gland, prostate, testis, and pancreas. -
Involvement in disease
Note=A chromosomal aberration involving FGFR1OP may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity. -
Sequence similarities
Belongs to the FGFR1OP family.
Contains 1 LisH domain. -
Cellular localization
Cytoplasm > cytoskeleton > centrosome. Associated with gamma-tubulin. - Information by UniProt
-
Database links
- Entrez Gene: 11116 Human
- Omim: 605392 Human
- SwissProt: O95684 Human
- Unigene: 487175 Human
-
Alternative names
- FGFR1 oncogene partner antibody
- FGFR1OP antibody
- Fibroblast growth factor receptor 1 oncogene partner antibody
see all
Images
-
Anti-FGFR1 Oncogene Partner antibody (ab229012) at 1/1000 dilution + Raji (human Burkitt's lymphoma cell line) whole cell lysate at 30 µg
Predicted band size: 43 kDa10% SDS-PAGE gel.
-
Paraffin-embedded human lung cancer tissue stained for FGFR1 Oncogene Partner using ab229012 at 1/500 dilution in immunohistochemical analysis.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab229012 has not yet been referenced specifically in any publications.